Does every woman require a post-lumpectomy mammogram and ultrasound before radiotherapy when negative margins

被引:0
|
作者
Pires, A. [1 ]
Rodrigues, J. [2 ]
Pereira, H. G. [1 ]
机构
[1] Portuguese Inst Oncol Porto, Radiat Oncol Dept, R Dr Antonio Bernardino De Almeida 865, P-4200072 Porto, Portugal
[2] Portuguese Inst Oncol Porto, Canc Epidemiol Grp, R Dr Antonio Bernardino De Almeida 865, P-4200072 Porto, Portugal
来源
CANCER RADIOTHERAPIE | 2022年 / 26卷 / 03期
关键词
Breast cancer; Breast conservative therapy; Residual disease; CARCINOMA-IN-SITU; BREAST-CONSERVING SURGERY; 20-YEAR FOLLOW-UP; CANCER; MASTECTOMY; THERAPY; IRRADIATION; SURVIVAL;
D O I
10.1016/j.canrad.2021.06.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. - Most studies regarding the value of post lumpectomy imaging (PLI) studies rely on mammography alone and are often focused on patients that present with suspicious microcalcifications or in situ disease. This way, its true benefit remains controversial, which explained the heterogeneity between centers. This is the first study to evaluate the role of mammography with breast and axillary ultrasound undertaken before radiotherapy in patients with conservatively managed invasive and/or in situ carcinoma with negative margins. Materials and Methods. - In this retrospective study, medical records for patients referred to our External Radiotherapy Unit between January 2018 and December 2019 were reviewed. Results. - A total of 1251 patients (1262 breasts) were analyzed. A total of 3.4% had suspicious findings for local residual breast disease, with 1.0% having a re-excision positive for residual malignancy. Presentation with microcalcifications alone ( OR = 4.854), extension of microcalcifications > 3 cm ( OR = 13.500), histologic subtype pure ductal carcinoma in situ (OR = 12.348), presence of invasive carcinoma < 1 mm of the pathological margins (OR = 4.630), stage pTis (5.630), and absence of invasive component ( OR = 4.629), were associated with an increased risk for residual malignancy. Only one patient ( 0.1%) had nodal residual involvement. Conclusion. - PLI detected residual local cancer in 1.0% of the patients. PLI plays an important role in the evaluation of patients undergoing breast-conserving therapy with negative margins. The major question that remains is whether it changes survival outcomes. (c) 2021 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:467 / 473
页数:7
相关论文
共 4 条
  • [1] Does every woman presenting with malignant calcifications require a post lumpectomy mammogram?
    Hálio Rodrigues-Duarte
    Thiemo J. A. van Nijnatten
    Tatiana Khoury
    Hiram Cody
    Stefanie Jacobs
    Maxine S. Jochelson
    Breast Cancer Research and Treatment, 2019, 176 : 401 - 406
  • [2] Does every woman presenting with malignant calcifications require a post lumpectomy mammogram?
    Rodrigues-Duarte, Halio
    van Nijnatten, Thiemo J. A.
    Khoury, Tatiana
    Cody, Hiram
    Jacobs, Stefanie
    Jochelson, Maxine S.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 176 (02) : 401 - 406
  • [3] is there a benefit for nodal evaluation as part of the post-lumpectomy imaging study before radiotherapy?
    Pires, A. M.
    Laranja, A. C. D. N.
    Sousa, F. F.
    de Castro, B.
    Sarandao, S.
    Costa, S.
    Fernandes, F.
    Pereira, H. G.
    ANNALS OF ONCOLOGY, 2021, 32 : S56 - S56
  • [4] NSABP B-51/RTOG 1304: Randomized phase III clinical trial evaluating the role of postmastectomy chest wall and regional nodal XRT (CWRNRT) and post-lumpectomy RNRT in patients (pts) with documented positive axillary (Ax) nodes before neoadjuvant chemotherapy (NC) who convert to pathologically negative Ax nodes after NC.
    Mamounas, Eleftherios P.
    White, Julia R.
    Bandos, Hanna
    Julian, Thomas B.
    Kahn, Atif J.
    Shaitelman, Simona Flora
    Torres, Mylin Ann
    McCloskey, Susan Ann
    Vicini, Frank A.
    Ganz, Patricia A.
    Paik, Soonmyung
    Gupta, Nilendu
    Costantino, Joseph P.
    Curran, Walter John
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)